<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659827</url>
  </required_header>
  <id_info>
    <org_study_id>AIPF001</org_study_id>
    <nct_id>NCT01659827</nct_id>
  </id_info>
  <brief_title>Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis</brief_title>
  <official_title>A Prospective, Randomized, Blinded, Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the AmnioFix Injectable human amniotic
      membrane is effective in the treatment of recalcitrant plantar fasciitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in American Orthopaedic Foot and Ankle Society (AOFAS) Hind Foot Score at 8 Weeks</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to return to normal activities</measure>
    <time_frame>Up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scale</measure>
    <time_frame>Weekly up to 8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Plantar Fasciitis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Initial injections of Marcaine and Saline (one each)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5cc AmnioFix Injectable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial injections of Marcaine and 0.5cc AmnioFix (one each)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.25cc AmnioFix Injectable</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial injections of Marcaine and 1.25cc AmnioFix (one each)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Marcaine</intervention_name>
    <description>Injection of 2cc of Marcaine</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>0.5cc AmnioFix Injectable</arm_group_label>
    <arm_group_label>1.25cc AmnioFix Injectable</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.5cc AmnioFix</intervention_name>
    <description>Injection of 0.5cc of AmnioFix Injectable</description>
    <arm_group_label>0.5cc AmnioFix Injectable</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1.25cc AmnioFix</intervention_name>
    <description>Injection of 1.25cc of AmnioFix Injectable</description>
    <arm_group_label>1.25cc AmnioFix Injectable</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Injection of 1.25cc of Saline</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years old.

          2. Both male and female patients will be selected.

          3. Plantar fasciitis has been treated with conservative usual care for at least 8 weeks,
             including at least three of the following modalities

               1. RICE

               2. Corticosteroid injection

               3. Stretching exercises

               4. NSAIDs

               5. Orthotics

          4. Females of childbearing potential must be willing to use acceptable methods of
             contraception (birth control pills, barriers, or abstinence).

          5. Patient understands and is willing to participate in the clinical study and can comply
             with weekly visits and the follow-up regimen.

          6. Patient has read and signed the IRB/IEC approved Informed Consent Form before
             screening procedures are undertaken.

        Exclusion Criteria:

          1. Prior surgery at the site

          2. Site that exhibits clinical signs and symptoms of infection

          3. History of chronic plantar fasciitis of more than twelve months

          4. Evidence of significant neurological disease of the feet

          5. Non Ambulatory Patients

          6. The presence of comorbidities that can be confused with or can exacerbate the
             condition including:

               -  Calcaneal stress fracture

               -  Nerve entrapment syndrome (baxter nerve syndrome or tarsal tunnel)

               -  Plantar fascial rupture

               -  Systemic disorders associated with enthesiopathy such as Gout, Reiters syndrome,
                  rheumatoid arthritis, etc.

               -  Achilles tendonitis

               -  Fat pad atrophy

               -  Fibromyalgia

          7. Patients with a history of more than two weeks treatment with immuno-suppressants
             (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to
             initial screening, or who receive such medications during the screening period, or who
             are anticipated to require such medications during the course of the study.

          8. Patients on any investigational drug(s) or therapeutic device(s) within 30 days
             preceding Screening.

          9. History of radiation at the site.

         10. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.

         11. Study foot has been previously treated with tissue engineered materials such as PRP
             within the last 30 days.

         12. Patients who are unable to understand the aims and objectives of the trial.

         13. Presence of any condition(s) which seriously compromises the subject's ability to
             complete this study, or has a known history of poor adherence with medical treatment.

         14. Pregnant or breast feeding. No pregnancy within the past 6 months.

         15. Allergy to Gentamycin Streptomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M. Zelen, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professional Education and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Professional Education and Research Institute</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professional Education and Research Institute</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2012</study_first_submitted>
  <study_first_submitted_qc>August 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2012</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

